Standout Papers

Selpercatinib in Patients With <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From th... 2022 2026 2023 2024115
  1. Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial (2022)
    Alexander Drilon, Vivek Subbiah et al. Journal of Clinical Oncology

Citation Impact

67 standout
Sub-graph 1 of 24

Citing Papers

Lung cancer statistics, 2023
2024 Standout
NF-κB in biology and targeted therapy: new insights and translational implications
2024 Standout
2 intermediate papers

Works of Guzmán Alonso being referenced

Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors.
2020

Author Peers

Author Oncology PRM RNMI Cancer Research Last Decade Papers Cites
Guzmán Alonso 172 159 18 73 31 301
Neel K. Kapasi 20 14 30 27 6 366
John Harrison 3 4 4 22 241
S. Siboni 1 19 20 2 45 2.0k
Nahas Gg 7 48 15 7 49 457
Susan D. Boulware 21 17 291 30 37 1.6k

All Works

Loading papers...

Rankless by CCL
2026